Ibudilast,a nonselective phosphodiesterase inhibitor,regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis

Abstract

We investigated the immunoregulatory effects of ibudilast, a nonselective phosphodiesterase inhibitor, at a clinically applicable dose (60 mg/day p.o. for four weeks) in multiple sclerosis (MS) patients. Sensitive real-time PCR for quantifying cytokine mRNA in the blood CD4- cells revealed that the ibudilast monotherapy significantly reduced tumour necrosis factor-a and interferon (IFN)-g mRNA and the IFN-g/interleukin-4 mRNA ratio, suggesting a shift in the cytokine profile from Th1 toward Th2 dominancy. In a flow cytometric analysis, natural killer T cells, which have been reported to relate to Th2 responses in MS and its animal model (experimental autoimmune encephalomyelitis), increased significantly after the therapy. None of the significant immunological changes were seen in healthy subjects or untreated MS patients. Ibudilast may be a promising therapy for MS and its clinical effects warrant further study.

Keywords

cytokine ibudilast multiple sclerosis natural killer T cell phosphodiesterase inhibitor therapy

Get full access to this article

View all access options for this article.

References

Link H. The cytokine storm in multiple sclerosis . Mult Scler 1998; 4: 12-15 .

Misu T , Onodera H , Fujihara K , Matsushima K , Yoshie O , Okita N et al. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling . J Neuroimmunol 2001; 114: 207-212 .

Rieckmann P , Albrecht M , Kitze B , Weber T , Tumani H , Broocks A et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis . Neurology 1994; 44: 1523-1526 .

Vartanian T , Li Y , Zhao M , Stefansson K. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis . Mol Med 1995; 1: 732-743 .

Selmaj K , Raine CS. Tumor necrosis factor mediates myelin damage in organotypic cultures of nervous tissue . Ann NY Acad Sci 1988; 540: 568-570 .

Araki M , Kondo T , Gumperz JE , Brenner MB , Miyake S , Yamamura T. Th2 bias of CD4- NKT cells derived from multiple sclerosis in remission . Int Immunol 2003; 15: 279-288 .

Yoshimura T , Nagao T , Nakao T , Watanabe S , Usami E , Kobayashi J et al. Modulation of Th1- and Th2-like cytokine production from mitogen-stimulated human peripheral blood mononuclear cells by phosphodiesterase inhibitors . Gen Pharmacol 1998; 30: 175-180 .

Sommer N , Loschmann PA , Northoff GH , Weller M , Steinbrecher A , Steinbach JP et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis . Nat Med 1995; 1: 244-248 .

Sommer N , Martin R , McFarland HF , Quigley L , Cannella B , Raine CS et al. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease . J Neuroimmunol 1997; 79: 54-61 .

10.

Suzumura A , Nakamuro T , Tamaru T , Takayanagi T. Drop in relapse rate of MS by combination therapy of three different phosphodiesterase inhibitors . Mult Scler 2000; 6: 56-58 .

11.

Aizawa T , Hasegawa T , Gotoh F , Katsunuma H , Araki G , Nara M et al. Clinical evaluation of KC-404 in the chronic stage of cerebrovascular disorders . Kiso-to-Rinsho (Clin Rep) 1984; 18: 5409-5433 (in Japanese).

12.

Shinohara Y , Kusunoki T , Nakashima M. Clinical efficacy of ibudilast on vertigo and dizziness observed in patients with cerebral infarction in the chronic stage-a double-blind, randomized, placebo-controlled trial with a run-in period . Shinnkeitiryougaku (Neurol Ther) 2002; 19: 177-187 (in Japanese, English abstract).

13.

Takahashi T , Kawakami Y , Takishima T , Mue S , Kobayashi S , Nemoto T et al. Clinical evaluation of KC-404, a new anti-asthmatic agent, in the treatment of bronchial asthma . Rinsho-Hyoka (Clin Eval) 1986; 14: 373-407 (in Japanese).

14.

Kishi Y , Ohta S , Kasuya N , Sakita S , Ashikaga T , Isobe M. Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall . Cardiovasc Drug Rev 2001; 19: 215-225 .

15.

Fujimoto T , Sakoda S , Fujimura H , Yanagihara T. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental auto-immune encephalomyelitis in Dark August rats . J Neuroimmunol 1999; 95: 35-42 .

16.

Rieckmann P , Weber F , Gunther A , Martin S , Bitsch A , Broocks A et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis . J Neuroimmunol 1996; 64: 193-200 .

17.

Yoshikawa M , Suzumura A , Tamaru T , Takayanagi T , Sawada M. Effects of phosphodiesterase inhibitors on cytokine production by microglia . Mult Scler 1999; 5: 126-133 .

18.

Ekholm D , Hemmer B , Gao G , Vergelli M , Martin R , Manganiello V. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein . J Immunol 1997; 159: 1520-1529 .

19.

Bielekova B , Lincoln A , McFarland H , Martin R. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1- mediated autoimmune diseases . J Immunol 2000; 164: 1117-1124 .

20.

Suzumura A , Ito A , Yoshikawa M , Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS . Brain Res 1999; 837: 203-212 .

21.

Lantz O , Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4-and CD4-8- T cells in mice and humans . J Exp Med 1994; 180: 1097-1106 .

22.

Bendelac A , Rivera MN , Park SH , Roark JH. Mouse CD1- specific NK1 T cells: development, specificity, and function . Annu Rev Immunol 1997; 15: 535-562 .

23.

Illes Z , Kondo T , Newcombe J , Oka N , Tabira T , Yamamura T. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy . J Immunol 2000; 164: 4375-4381 .

24.

Miyamoto K , Miyake S , Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells . Nature 2001; 413: 531-534 .